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Background: Recently, the phase III PALETTE study introduced pazopanib (Votrient®) as treatment for adult patients
with locally advanced or metastatic non-liposarcoma soft tissue sarcoma after prior treatment with doxorubicin
and/or ifosfamide. Pneumothorax was reported as adverse event in 8 of 246 treated patients (3.3%) in that study.
This case series presents the incidence and clinic of this complication in the Leiden University Medical Centre.
Cases: Forty-three patients were treated with pazopanib of which six patients (14.0%) developed a pneumothorax.
These six patients were treated for malignant peripheral nerve sheath tumour, angiosarcoma, synovial sarcoma,
fibromyxomatoid sarcoma, pleomorphic sarcoma and endometrial stromal sarcoma. All six patients had subpleural
pulmonary or pleural metastases at the start of pazopanib and the pneumothorax developed during or shortly after
treatment with pazopanib and was difficult to treat.
Discussion: The incidence reported by us is higher than the incidence in the PALETTE study. Trials with pazopanib
in renal cell carcinoma, urothelial carcinoma and cervix carcinoma did not report pneumothorax as an adverse
event, suggesting pneumothorax as a specific adverse event in soft tissue sarcoma patients treated with pazopanib.
This may be related to the fact that there is often pleural metastatic involvement and cystic degeneration due to
pazopanib treatment may add to the risk.
Conclusion: The risk of an, often difficult to treat, pneumothorax during pazopanib therapy should be discussed
with the patient before initiation of treatment for a pulmonary metastasized sarcoma and physicians should be
alert to the occurrence of such an event.
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metastasesBackground
Soft tissue sarcomas (STS) are rare mesenchymal tu-
mours originating from visceral and connective tissue.
This group of tumours accounts for approximately one
percent of all malignancies and consists of more than 50
histological subtypes [1]. The only curative treatment is
surgical resection with large margins with or without ad-
juvant radiotherapy [1]. Treatment for locally advanced
and metastatic disease is usually palliative and was until* Correspondence: A.J.Verschoor@lumc.nl
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article, unless otherwise stated.recently mostly confined to anthracyclin or ifosfamide
based chemotherapy, apart from specific chemotherapy
regimens used for specific subgroups [1]. Reported re-
sponse rates vary between 16-27% and median survival
is reported to be 12 months [2]. Trabectedin was intro-
duced recently for STS, mainly for patients with (myx-
oid) lipo- and leiomyosarcomas [3,4].
More recently, the phase III PALETTE study [5] intro-
duced pazopanib (Votrient®) as treatment for adult pa-
tients with non-lipomatous advanced STS who have
received prior chemotherapy for metastatic disease or
who have progressed within 12 months after (neo)ioMed Central Ltd. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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survival of 4.6 months for pazopanib versus 1.6 months
in the placebo arm. Pazopanib is an oral anti-angiogenic
multi-targeted tyrosine kinase inhibitor with activity
against vascular endothelial growth factor receptors
(VEGFR) 1, 2 and 3, platelet derived growth factor re-
ceptors and KIT. In the PALETTE study, treatment with
pazopanib was complicated by the occurrence of a
pneumothorax in 8 of the 246 patients. This case series
reports on the incidence and clinic of this complication
in all consecutive patients treated at the Leiden Univer-
sity Medical Centre.
Cases
In our institution, 43 STS patients were treated with
pazopanib, of which 39 had pulmonary metastases and
36 of these patients had pleural or subpleural pulmonary
metastases. Treatment was complicated by a pneumo-
thorax in six (14.0%) patients.
The first patient is a 24-year old male, with a malig-
nant peripheral nerve sheath tumour of the left brachial
plexus, diagnosed three years before. Initial treatment
consisted of local resection and irradiation, repeated one
year later because of local recurrence. Pulmonary metas-
tases, some localised pleural, were found seven months
later for which six cycles of 3-weekly doxorubicinFigure 1 CT scans of patient 1. A and B: CT scan of the thorax at start o
hypodensities suggesting necrosis (A, arrow) and showing a pulmonary me
presenting with a left-sided pneumothorax (D), showing progressive hypod
cavitation in the metastasis in the right lung (D, arrow).75 mg/m2 was initiated. Progressive disease was diag-
nosed six months after the first doxorubicin cycle and
treatment with pazopanib was started. A CT scan at the
start of pazopanib showed a necrotizing metastasis in
the left lung (Figure 1A, B). A month later a left-sided
pneumothorax occurred after a skiing trip at 3000
meters height, persisting after drainage and later also a
right sided pneumothorax occurred. The CT scan de-
tecting the pneumothorax on the left side, also showed
cystic degeneration of metastases in the right lower lobe
(Figure 1C, D). The persistent bilateral pneumothorax
was complicated by a pyothorax on the left side. He died
six months after the start of pazopanib, which was con-
tinued until his death.
Patient 2 is a 79-year old male, who was diagnosed
two years before with an angiosarcoma of the scalp.
Primary treatment was combined paclitaxel and radio-
therapy. However, one year later a local recurrence was
diagnosed and a CT scan showed pulmonary metastases,
of which some were pleural, for which 3-weekly doxo-
rubicin 75 mg/m2 was started. The local recurrence
was progressive after six months and pazopanib was ini-
tiated, which was stopped three months thereafter
because of progressive disease. Some of the pulmonary
metastases already showing cavitation at start of pazopa-
nib (Figure 2A) were increasing in number, size andf pazopanib, showing a pleural metastasis of the left lung with central
tastasis in the right lung (B, arrow). C and D: CT scan, when
ensity of the pleural metastasis on the left side (C, arrow) and central
Figure 2 CT scans and X-thorax of patient 2. A: CT scan at start of pazopanib showing metastases in both lungs with a large necrotizing
metastasis on the left side. The pleural metastasis indicated by the arrow is also visible in B, which is a CT scan after 3 months of pazopanib
treatment, now showing cavitations. C is also an image from the CT scan after 3 months of pazopanib treatment showing a metastasis (arrow)
with cavitation next to the pleura. D: The X-thorax shows the right sided pneumothorax. The visceral pleural line is indicated by the arrow.
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after the start of pazopanib a right sided pneumothorax
occurred (Figure 2D), which was treated with drainage,
but without pleurodesis, however it recurred one week
later and again drained. A month thereafter a left-sided
pneumothorax was diagnosed, which was left untreated.
He died one week later due to disease progression, four
months after the start of pazopanib.
The third patient is a 34-year old male, three years be-
fore diagnosed with a synovial sarcoma of the left femur
with synchronous lung metastases, some with a pleuralFigure 3 CT scans of patient 3. Routine follow-up CT scan showing the pn
B shows a pleural metastasis.localisation, and malignant pleural effusion. Treatment
consisted of resection of the primary tumour and doxo-
rubicin/ifosfamide chemotherapy followed by pulmonary
metastasectomy and isolated melphalan lung perfusion.
Treatment with trabectedin was started, but stopped
after nine cycles because of progressive disease and
pazopanib was started. He was treated for a remarkable
15 months when progression occurred and a hydropneu-
mothorax was diagnosed on a routine follow-up CT scan
(Figure 3A, B), treated with drainage and talc pleurod-
esis. Pazopanib was stopped. The CT scan did not showeumothorax on the right side. A shows one of the pulmonary metastasis,
Figure 4 CT scan of patient 4. The CT scan shows the massive
pulmonary metastases and a left-sided pneumothorax.
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sion recurred, and persisted until he died 2 months
later.
The fourth patient is a 53-year old female, who had re-
section of a low-grade fibromyxomatoid sarcoma of the left
lower extremity 13 years before. Nine years later, pulmon-
ary, liver and lymph node metastases were diagnosed,
treated with 2 cycles of liposomal doxorubicin, which was
stopped because of toxicity. Some of the pulmonary metas-
tases were localised adjacent to the pleura. Treatment was
continued with low dose doxorubicin weekly for 3 months,
which was repeated one year later because of progressive
disease. Three months after the last doxorubicin treatment
progressive disease was diagnosed and pazopanib was pre-
scribed. After seven months treatment with pazopanib she
developed a left-sided pneumothorax (Figure 4), success-
fully treated with drainage. No cavitation of the metastasesFigure 5 CT scans of patient 5. A: CT scan before the start of pazopanib
arrow. B: Routine follow-up CT scan during pazopanib treatment showing
the right lung is now showing cavitation.was found. At the moment, treated for 31 months with
pazopanib, she has stable disease.
Patient five is a 72-year old female, who presented
with a high grade undifferentiated pleomorphic sarcoma
of the right lower extremity with pulmonary metastases,
of which some are localised next to the pleura, one year
before. She was treated with local resection, radiotherapy
and 3-weekly doxorubicin 75 mg/m2. Five months after
the start of doxorubicin progressive disease was diag-
nosed and pazopanib was prescribed (Figure 5A). After
two months of treatment she developed a left-sided
pneumothorax, treated with drainage and pleural
rubbing (Figure 5B). Part of the pulmonary metastases
showed cavitation. During admission a right-sided
pneumothorax occurred and was drained successfully.
However, she died one week later due to progressive
disease.
The sixth patient is a 40-year old female diagnosed
with a low grade endometrial stromal sarcoma, six years
before, after a uterus extirpation for uterine myomatosis.
When she presented four years later with thoracic pain,
CT scan of the thorax showed a large mediastinal mass
and pulmonary metastases, also localised next to the
pleural space. Treatment with doxorubicin was started
and resulted in partial regression of the tumour masses.
Eighteen months later pazopanib was started under the
supervision of the reference centre because of progres-
sion of the pulmonary metastases. Due to liver toxicity
the pazopanib dose was tapered to a minimum dose of
200 mg with short pauses in treatment, however treat-
ment was successful (Figure 6A, B). Treatment was per-
manently stopped after 33 months because of a bilateral
pneumothorax and disease progression (Figure 6C). She
was successfully treated with drainage.
Discussion
The incidence of pneumothorax of 14.0% in our institu-
tion was higher than the previous reported incidenceshowing multiple metastases in the right lung, one is indicated by the
the left-sided pneumothorax and the earlier mentioned metastasis in
Figure 6 CT scan of patient 6. A: CT scan at start of pazopanib showing a metastasis in the right lower lobe with a diameter of 49.6 mm. B: CT scan
after 12 weeks of pazopanib (6 weeks of treatment and 6 weeks on hold due to liver toxicity), showing a decrease in diameter of the metastasis to
33.1 mm. C: CT scan showing the bilateral pneumothorax.
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vide the incidence of secondary spontaneous pneumo-
thorax in STS patients, but it is probably uncommon.
Other trials with pazopanib in for example urothelial
cancer, renal cell cancer, pancreatic neuroendocrine
tumours and cervical cancer did not report pneumo-
thorax as an adverse event [6-11]. Trials with sunitinib,
another VEGFR inhibitor, in renal cell carcinoma also
do not report pneumothorax as an adverse event
[12,13]. Only, two cases are published in literature of
patients with a spontaneous pneumothorax during
sunitinib treatment for renal cell carcinoma [14,15].
This suggests that this is a specific adverse event in
metastatic STS treated with pazopanib, however, it
could still be due to underreporting in other studies
or due to the natural course of this disease that pre-
dominantly metastasizes to the lungs.
One of the proposed mechanisms is necrosis of a
metastasis due to therapy, resulting in a pleural defect.
Another possible explanation would be a check valve
mechanism due to compression of bronchioles by a
lung metastasis causing hyperinflation of a lung seg-
ment and rupture of lung parenchyma [16]. In our pa-
tients all cases of pneumothorax were related to pleural
or subpleural lung metastases, and were observed in
both progressive and responding patients. Smoking is a
risk factor for primary spontaneous pneumothorax, but
only one of our six patients had a smoking history.
We do not think smoking history is relevant for the oc-
currence of a pneumothorax in these patients. As with
other cancer related pneumothoraxes they were diffi-
cult to treat. One of the explanations for the difficult
treatment in these patients could be the use of pazopa-
nib, which inhibits angiogenesis and thereby tissue
regeneration.
A larger series is needed in a case control setting to
gain more understanding of this phenomenon.Conclusion
The risk of a difficult to treat pneumothorax during
pazopanib therapy should be discussed with the patient
before initiation of treatment for a pulmonary metasta-
sized sarcoma and physicians should be alert to the oc-
currence of such an event.
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